GlassScriptPhysician profile
Louis J Cuzzone
NPI 1407957103
$8,777.22
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,868 · 2020: $2,352 · 2021: $2,776 · 2022: $681 · 2023: $55.20 · 2024: $46.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $574.89 | 2019-2022 | |
| Ucb, INC. | $538.34 | 2019-2022 | |
| Abbvie INC. | $527.55 | 2021-2023 | Botox |
| Allergan, INC. | $459.66 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $398.01 | 2019-2022 | |
| Mdd US Operations, LLC | $380.48 | 2019-2023 | Gocovri |
| Genzyme Corporation | $379.72 | 2019-2022 | |
| Genentech USA, INC. | $379.59 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $368.44 | 2019-2022 | |
| Kyowa Kirin, INC. | $303.47 | 2019-2022 | |
| Amgen INC. | $298.93 | 2019-2022 | |
| Csl Behring | $283.28 | 2019-2022 | |
| Sk Life Science, INC. | $277.27 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $267.63 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $252.57 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Cuzzone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.